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Abstract
Background In spite of the proven efﬁcacy of pharma-
cological prophylaxis of heterotopic ossiﬁcation following
total hip arthroplasty, its routine use is still debated, and no
data are available regarding the adherence to its adminis-
tration in clinical practice.
Materials and methods In this prospective, observational,
multicenter study, 480 consecutive patients operated on for
primary total hip arthroplasty during the year 2009 were
followed radiographically for 12 months after surgery in
order to assess the incidence of periprosthetic heterotopic
ossiﬁcation. Surgeons were free to choose whether to
administer pharmacological prophylaxis, and were asked to
keep a record of the duration of the prophylaxis (if used) or
the reasons for not using it. To facilitate the statistical
analysis, all of the participating centers agreed to use only
one drug (celecoxib) that had already proven to be effective.
Results 368 patients were administered celecoxib and
112 patients did not receive any prophylaxis. Reported
reasons for not administering celecoxib prophylaxis were
the surgeon’s opinion that prophylaxis was not needed on a
routine basis (84/112 patients, 75%), previous history of
gastrointestinal bleeding (17.8%), and concomitant car-
diorenal pathologies (7.1%). The overall incidence of het-
erotopic ossiﬁcation in the celecoxib-treated patients was
23% (no cases of Brooker grade 3 or 4 ossiﬁcations),
compared to 55% in the untreated patients (Brooker grade
3 and 4: 8.9%). Multivariate analysis showed that cele-
coxib prophylaxis was the single most important variable
when predicting the occurrence of heterotopic ossiﬁcation.
Conclusions This study conﬁrms the efﬁcacy and toler-
ability of celecoxib for the prophylaxis of heterotopic
ossiﬁcation after total hip arthroplasty, and shows how the
surgeon’s belief that routine prevention is not required still
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Introduction
Despite the evidence that heterotopic ossiﬁcation (HO)
can occur with an incidence ranging from 15 to 90%
after conventional total hip arthroplasty (THA), and that
about one-quarter of those patients will develop severe
HO (Brooker [1] grades 3 and 4) which may be asso-
ciated with impaired range of motion (ROM) at the hip
joint and decreased functional outcome [2–5], a recent
review article has suggested that routine HO prophylaxis
is not warranted for routine THA [6], while it has been
advocated for all surface replacements, given the higher
incidence of complications compared to that for THA
[7].
Several patient-related risk factors have been implicated
in the development of HO after THA, such as age, male
sex, hypertrophic osteoarthritis, ankylosing spondylitis,
diffuse idiopathic skeletal hyperostosis, and history of HO
[3, 8, 9]. However, since soft-tissue trauma is the main
initiating factor in HO development [10, 11], and given the
fact that HO may develop even in the absence of any
known risk factor, the question of how to determine whe-
ther a patient should receive HO prophylaxis remains
unresolved.
Low-dose irradiation after total hip arthroplasty has
been reported to be effective in the prevention of HO [12,
13], but extensive use of irradiation is limited by logistic
problems, costs, and concerns about irradiating a vast
population of patients. On the contrary, nonsteroidal anti-
inﬂammatory drugs like indomethacin provide easy-to-use
and effective prophylaxis that can be administered in any
hospital, even though side effects can limit its use [14–18].
As a valid alternative, celecoxib has been previously
reported to be as effective as indomethacin but with fewer
side effects [19], and to be better than ibuprofen [20].
In spite of this large body of evidence in favor of
pharmacological prophylaxis, there is still a lack of con-
sensus as to the need for extensive prevention of HO after
THA.
The aim of this prospective, multicenter study was to
observe adherence to the routine use of pharmacological
prophylaxis of HO after primary THA in six orthopedic
wards in two Italian central regions (Abruzzo and Molise),
and to correlate that with the incidence of HO.
Materials and methods
This study, performed under the aegis of GAMOT (Gruppo
Abruzzo-Molise Ortopedici e Traumatologi), included 504
patients (126 males and 378 females) who were affected by
hip osteoarthritis and were undergoing surgery to implant a
cementless total hip arthroplasty on six orthopedic wards in
Italy [Ospedale S. Salvatore, L’Aquila (AQ): 95 patients;
Ospedale di Sulmona (SU): 86; Ospedale G. Bernabeo,
Ortona (OR): 83; Ospedale di Teramo (TE): 83; Ospedale
di Campobasso (CB): 82; Ospedale SS. Annunziata, Chieti
(CH): 75] during the year 2009. Twelve (2.4%) of these
patients were lost to follow-up and so were not included in
this review.
All the patients gave their informed written consent to
collect their data prior to being included into this pro-
spective, observational, multicenter study. The study was
authorized by the local ethical committee and performed in
accordance with the ethical standards of the 1964 Decla-
ration of Helsinki as revised in 2000.
Exclusion criteria were previous surgery on the same
hip, ankylosing spondilitis, diffuse idiopathic skeletal
hyperostosis, neurologic diseases—all conditions that are
known or suspected to increase the risk of development of
heterotopic ossiﬁcation [21, 22]. No patient received
radiotherapy after the THA implant for HO prevention.
Preoperative diagnosis, surgical approach (posterolateral
or direct lateral), HO prophylaxis, and its side effects were
evaluated by a local investigator on each orthopedic ward.
Surgeons were left free to choose whether or not to
administer pharmacological prophylaxis of HO on the basis
of their experience and their clinical judgement, but for
those patients who did not receive prophylaxis, the sur-
geons were asked to make a record of the reason for their
choice. To unify the data in this observational study and
allow further statistical analysis, all of the participating
centers agreed to use only celecoxib for the pharmaco-
logical prophylaxis of HO.
Heterotopic ossiﬁcation was evaluated by a radiologist
blinded to the treatment the patient received. The grading
of heterotopic ossiﬁcation was performed using antero-
posterior radiographs of the hip at 12 months after surgery,
according to the classiﬁcation of Brooker et al. [1]. This
system classiﬁes the absence of heterotopic bone forma-
tions as grade 0, the presence of islands of bone within the
soft tissues of the treated hip as grade I, the occurrence of
bone spurs and a gap between opposing bone surfaces of
[1 cm as grade II, the presence of bone spurs and a gap of
\1 cm as grade III, and a bridge of bone across the joint as
grade IV. Heterotopic ossiﬁcation of grade III or more is
associated with increasing impairment of range of motion
and function.
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the occurrence of side effects were not included in the
statistical evaluation of heterotopic bone formation.
To analyze sample characteristics, Fisher’s exact test
was used for categorical variables or linear regression
models for continuous variables. Statistical signiﬁcance
was deﬁned as a P value of less than 0.05, and 95% CI.
Results
At follow-up, 492 patients were available; 380 (77.2%)
patients were administered pharmacological prophylaxis
(celecoxib 200 mg twice per day, for 17 ± 3d a y s ,am i n i -
mum of 14 and a maximum of 20 days after surgery, starting
the day after the surgical procedure in all cases). Twelve
(3.2%) patients treated with celecoxib reported minor gas-
trointestinal side effects that required treatment discontinu-
ation after a mean of 9 days (range 7–15 days) from the start
of treatment, and were not included in the review of HO any
further. No patient received indomethacin.
One hundred twelve (22.8%) patients did not receive
any prophylaxis for HO; reported reasons for not admin-
istering prophylaxis were the surgeon’s opinion that pro-
phylaxis was not needed on a routine basis (84/112
patients, 75%), a previous history of gastrointestinal
bleeding (20/112; 17.9%), or concomitant cardiorenal
pathologies (8/112; 7.1%) (Fig. 1).
The overall incidence of heterotopic ossiﬁcation in the
celecoxib-treated patients was 23.1% (85/368, no Brooker
grade 3 or 4 ossiﬁcations), compared to 55.3% (62/112) in
the untreated group. In the latter, 10/112 (8.9%) patients
showed Brooker grade 3 and 4 ossiﬁcation. Grades 1, 2, 3,
and 4 HO were respectively seen in 27 (24.1%), 25
(22.3%), 8 (7.1%), 2 (1.8%) untreated patients; grades 1
and 2 HO were observed in 70 (19.0%) and 15 (4.1%) of
the patients treated with celecoxib (Fig. 2). The overall
difference in HO in the two groups (23 vs. 55%) was sta-
tistically signiﬁcant (P\0.0001).
Logistic regression showed that the occurrence of HO
did not correlate with sex (P = 0.66), preoperative diag-
nosis (P = 0.14), hospital (P = 0.24), or surgical approach
(P = 0.09), while celecoxib prophylaxis was the single
most important variable in predicting the occurrence
of heterotopic ossiﬁcation (P\0.0001; O.R.: 4.1; CI:
2.6–6.4).
Discussion
There is a large body of evidence on the incidence of HO
after THA; in the literature, it ranges from 15 to 90%, with
the rate of severe HO (Brooker grades 3 and 4) at around
10%, in the absence of adequate prophylaxis [2]. Severe
HO have been shown to be associated with impaired range
of motion (ROM) at the hip joint and decreased functional
outcome [3–5]. Even though several patient-related risk
factors for developing ectopic ossiﬁcation are well known
[18, 22], as stated by Kolbl and Knelles et al. [13]: ‘‘on an
absolute scale considerably more patients without risk
factors develop heterotopic ossiﬁcation because the num-
ber of patients with risk factors is low compared to all
patients receiving total hip replacement. In this respect,
prophylactic treatment after total hip replacement seems
advocated for all patients.’’ Contrary to this statement,
other authors have recently suggested that ‘‘there is cur-
rently little evidence to support the routine use of pro-
phylaxis for heterotopic ossiﬁcation in arthroplasty
patients’’ [6], while pharmacological prophylaxis has been
advocated for all surface replacements, given the higher
incidence of the complication compared to THA [7]. More
recently, HO prophylaxis has also been advocated after hip
arthroscopy for femoroacetabular impingement syndrome
[23].
This is, to our knowledge, the ﬁrst prospective, obser-
vational, multicenter study ever performed to investigate
Fig. 1 Surgeons self-reported reasons for not administering pharma-
cological prophylaxis in patients that underwent total hip replacement
in this study (N = 112)
Fig. 2 Incidence of heterotopic ossiﬁcation in the celecoxib (N =
368) and in the untreated (N = 112) groups
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laxis after THA in patients without known risk factors for
HO in different orthopedic wards of general hospitals in
Italy and in Europe.
The incidence of HO observed in the present study in
patients who were not treated with prophylactic measures
and did not have any known risk factor is perfectly in
keeping with those previously reported in the literature.
Our study conﬁrms the efﬁcacy of administering celecoxib
postoperatively to prevent this complication and the rela-
tively low rate of side effects and dropouts connected with
this prophylaxis. Our data also illustrate the reported rea-
sons for not treating patients on a routine basis. In this
regard, the belief that routine HO prophylaxis is not jus-
tiﬁed for patients without known risk factors for HO is the
main reported cause for not administering pharmacological
prophylaxis in our study. This may be due to the conﬂicting
statements in the literature that are in favor of [13–20]o r
against the routine use of prophylaxis [6]. Other reported
reasons for not performing pharmacological prophylaxis
include risk factors for potential side effects connected
with the use of anti-inﬂammatory drugs [24]. The impor-
tance of minimizing possible side effects in the clinical
setting may also explain the universal preference of all the
surgeons included in this survey for celecoxib rather than
other possible nonsteroidal anti-inﬂammatory drugs. In
fact, celecoxib has previously been reported to be equally
effective but associated with fewer side effects than indo-
methacin [19, 25], while it has proven more effective than
ibuprofen [20]. Considering the reasons for not adminis-
tering pharmacological prophylaxis critically, in the light
of the most recent reports on the safety of celecoxib used in
association with proton pump inhibitors, even in patients
with severe gastrointestinal risk factors [26, 27], it is
questionable as to whether previous gastrointestinal
bleeding should be considered a contraindication to phar-
macological prophylaxis of HO with celecoxib. On the
other hand, there is no clear evidence that short-term
administration (less than 20 days) of celecoxib or any other
nonsteroidal anti-inﬂammatory drugs can have serious side
effects on the cardiorenal apparatus [28].
Limits of the present study include:
– The absence of a comparator group of patients treated
with other nonsteroidal anti-inﬂammatory drugs
– The absence of a placebo control group
– The patient’s allocation to the two groups based on the
surgeon’s choice
– The lack of complete information on comorbidities and
their relative incidences
– The lack of information on possible subclinical side
effects of the prophylaxis (e.g., the incidence of lower
gastrointestinal tract bleeding)
– The lack of demonstration that prophylactic treatment
with lower doses or a shorter duration would have been
equally effective
In spite of these limitations, the present study conﬁrms
the efﬁcacy and safety of pharmacological prophylaxis of
HO with a selective cycloxygenase-2 inhibitor, and favors
the routine administration of this prophylaxis after THA—
even in patients without known risk factors for this com-
plication, given the high incidence of complications in
untreated patients.
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